Q2 Biotech And Specialty Pharma News, In Brief
Theravance Reports Positive Relovair Data
You may also be interested in...
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.
Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.